Companies

Pure Bioscience

PURE
$0.06
▼ $0.01 (−14.29%) today
Markets closed · 10:34pm ET

PURE at a Glance

Earnings
Next report
Dec 16, 2026

PURE

About Pure Bioscience

PURE Bioscience, Inc. (OTCQB: PURE) develops and commercializes proprietary antimicrobial products, primarily for the food and beverage industry, including food processing and dairy applications. Its technology platform is based on patented, stabilized ionic silver; its products contain silver dihydrogen citrate (SDC), a broad-spectrum, non-toxic antimicrobial agent that formulates well with other compounds. The company positions SDC as offering stronger efficacy, reduced toxicity and mitigation of bacterial resistance compared with incumbent treatment chemistries, though its products are typically more expensive. PURE sells through a distributor network to end users and through technology partnerships. It relies on third-party vendors to manufacture its products and earns small royalty revenue. In fiscal 2026 (ended July 31, 2026) it generated about $2.3 million in net product sales and remained loss-making. It funds operations largely through convertible notes from related parties, part of which are past due, and it carries a stockholders' deficiency. Updated

PURE Coverage

Frequently Asked Questions

What does Pure Bioscience do?

PURE Bioscience, Inc. (OTCQB: PURE) develops and commercializes proprietary antimicrobial products, primarily for the food and beverage industry, including food processing and dairy applications.